Related Experiment Video

Updated: Mar 31, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma

Hebing Zhou1, Jinqing Li2, Yuan Jian3

  • 1Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.

Experimental Hematology
|October 28, 2015
PubMed

Insights

Arsenic trioxide (ATO) and recombinant mutant human TRAIL (rmhTRAIL) show combined anti-cancer effects in multiple myeloma (MM) cells. This combination therapy may offer a new treatment strategy for MM by affecting protein expression and inducing cell death.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Arsenic trioxide (ATO) and recombinant mutant human TRAIL (rmhTRAIL) demonstrate anti-tumor activity in various cancers.
  • The combined efficacy and underlying mechanisms of ATO and rmhTRAIL in multiple myeloma (MM) remain uninvestigated.

Purpose of the Study:

  • To evaluate the synergistic effects of ATO and rmhTRAIL on proliferation inhibition and apoptosis induction in MM cell lines.
  • To elucidate the molecular mechanisms of the ATO and rmhTRAIL combination therapy in MM using proteomic analysis.

Main Methods:

  • Utilized MM cell lines (RPMI8226 and U266) to assess single-agent and combination treatments.
  • Employed high-performance liquid chromatography and mass spectrometry (HPLC-MS) for differential protein expression analysis.
  • Investigated proliferation inhibition and apoptosis induction as key efficacy endpoints.

Main Results:

  • ATO and rmhTRAIL exhibited synergistic or additive effects on inhibiting proliferation and inducing apoptosis in MM cells.
  • Proteomic analysis revealed alterations in protein expression profiles following combination treatment.
  • The combination's mechanism involves the regulation of specific proteins influenced by both ATO and rmhTRAIL.

Conclusions:

  • The combination of ATO and rmhTRAIL presents a promising therapeutic strategy for multiple myeloma.
  • Understanding the protein-level mechanisms provides a foundation for further clinical development.
  • This study supports the potential of novel combination treatments for MM patients.

More Related Videos

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K